Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer

ClinicalTrials.gov ID: NCT04067960

Public ClinicalTrials.gov record NCT04067960. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 6, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Precision Pharmacogenomics in Cancer Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer. Pharmacogenomics is the study of how genes may affect the body's response to and interaction with some prescription medications. Genes, which are inherited from parents, carry information that determines things such as eye color and blood type. Genes can also influence how patients process and respond to medications. Depending on the genetic makeup, some medications may work faster or slower or produce more or fewer side effects. Pharmacogenomics testing may help doctors learn more about how patients break down and process specific medications based on their genes and improve the quality of life of cancer patients receiving clinical care.

Study identification

NCT ID: NCT04067960
Recruitment status: Completed
Study type: Interventional
Phase: Early Phase 1
Lead sponsor: Mayo Clinic; Other
Enrollment: 197 participants

Conditions and interventions

Conditions

Interventions

Procedure · Other

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 5, 2019
Primary completion: Oct 5, 2022
Completion: Oct 5, 2022
Last update posted: Aug 13, 2024

2019 – 2022

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Mayo Clinic in Arizona	Scottsdale	Arizona	85259	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04067960, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 13, 2024 · Synced Sep 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04067960 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →